Secker-Walker L M, Prentice H G, Durrant J, Richards S, Hall E, Harrison G
Royal Free Hospital and School of Medicine, London.
Br J Haematol. 1997 Mar;96(3):601-10. doi: 10.1046/j.1365-2141.1997.d01-2053.x.
Cytogenetic classification of 350 adults with acute lymphoblastic leukaemia on MRC UKALL XA trial showed the following statistically significant associations: t(9;22) (11%) increased with increasing age and leucocyte counts (WBC) and most had a C/pre-B immunophenotype. t(4;11) (3%) was associated with higher WBCs, increasing age and null immunophenotype. Other abnormalities of 11q (abn11q) (4%) were associated with male sex and T-cell ALL. High hyperdiploidy (7%) and abn9p (5%) decreased with increasing WBC. High hyperdiploid patients were younger and tended to have C/pre-B ALL. Triploidy/tetraploidy (3%) decreased and pseudodiploidy (11%) increased with increasing WBC. Cytogenetic classification was prognostically important (chi-square for heterogeneity of classification = 53.56; P < 0.0001) and added significance to age, sex and WBC. A poor prognosis for patients classed as t(9;22) (13% disease-free survival at 3 years), as t(4;11) 24% at 3 years) and hypodiploid (11% at 3 years), and good prognosis for abn12p (4% of subjects) and high hyperdiploidy (74% and 59% at 3 years respectively) were statistically significant, but the 54% 3-year disease-free survival for patients with t(1;19) was not. The prognosis of patients classed as t(9;22) was independent of other single variables. Abn12p, abnormalities of 11q (including t(4;11) cases) and hypodiploidy added prognostic significance to all other variables combined.
在英国医学研究理事会(MRC)UKALL XA试验中,对350例成人急性淋巴细胞白血病患者进行的细胞遗传学分类显示出以下具有统计学意义的关联:t(9;22)(11%)随年龄和白细胞计数(WBC)增加而增多,且大多数具有C/前B免疫表型。t(4;11)(3%)与较高的白细胞计数、年龄增长和无免疫表型相关。11号染色体长臂其他异常(abn11q)(4%)与男性及T细胞急性淋巴细胞白血病相关。高超二倍体(7%)和9号染色体短臂异常(abn9p)(5%)随白细胞计数增加而减少。高超二倍体患者较年轻,且倾向于患有C/前B急性淋巴细胞白血病。三倍体/四倍体(3%)随白细胞计数增加而减少,假二倍体(11%)则随白细胞计数增加而增多。细胞遗传学分类在预后方面具有重要意义(分类异质性的卡方值=53.56;P<0.0001),并增加了年龄、性别和白细胞计数的预后价值。分类为t(9;22)的患者预后较差(3年无病生存率为13%),t(4;11)的患者为24%(3年),亚二倍体患者为11%(3年),而12号染色体短臂异常(abn12p)(4%的受试者)和高超二倍体患者(3年分别为74%和59%)预后良好,这些差异具有统计学意义,但分类为t(1;19)的患者3年无病生存率为54%,差异无统计学意义。分类为t(9;22)的患者预后与其他单一变量无关。12号染色体短臂异常、11号染色体长臂异常(包括t(4;11)病例)和亚二倍体增加了所有其他变量综合起来的预后价值。